Allergan Retinoid Therapeutics Inc., Hoffmann-La Roche regulatory update

ALRIZ asked the U.S. Patent and Trademark Office to start an interference between ALRIZ's ALRT 1057 (9-cis-retinoic acid) and Hoffmann La-Roche's U.S. Patent No. 5,428,071, which covers oral and topical uses of 9-cis-retinoic acid to prevent and treat epithelial tumors.

Hoffmann La-Roche filed for patent protection on Jan. 22, 1992, and it issued last week. The application for the pending ALRIZ patent was filed on Dec. 18, 1991. ...